Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

For biopharma executives who are between roles, navigating the transitionary time can be challenging. However, they can ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities, ...

Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

What matters to life sciences candidates when they are considering job opportunities? BioSpace surveyed our life sciences ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Seaport Therapeutics, kick started by the former leaders of Karuna Therapeutics, has raised a $225 million, oversubscribed ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

United States Pharmacopeia is recruiting expert volunteers from academia, industry, regulatory and healthcare to develop, ...